Drug Pipeline

TNX-103 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
3
Phase 3
1
Top Sponsors
Active Studies by Phase
Phase 3
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05983250 LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF Pulmonary Hypertension Recruiting
NCT07288398 LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pulmonary Hypertension Associated With HFpEF Recruiting
NCT07436689 Long-Term Open-Label Extension Study of Oral Levosimendan Pulmonary Hypertension Associated With HFpEF Enrolling by Invitation
Sponsors Running TNX-103 Trials
Tenax Therapeutics, Inc. (3)
Disease Areas
Hypertension (3) Heart Failure (2)
Get alerts when TNX-103 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free